Dr. Hawley
The first 50 guests will receive a free lunch, and other freebies will be given away to those who ask questions and engage the panel in a meaningful way.
Panelists will include former research scientists who now work in a range of science-related fields. They are expected to discuss their personal journeys as biomedical scientists, how they arrived in their present occupations, and offer advice to others who may be interested in a science career away from the research bench.
The panelists are Amanda Hawley, PhD, Brandon Hillman, PhD, Agnes Lenagh, PhD, and Gary Madsen, PhD
Dr. Hillman
Dr. Hawley is a Business Development & Intellectual Property Associate Manager at LI-COR Biosciences, a biotech company based in Lincoln, Neb. A former Licensing Associate at UNeMed, Dr. Hawley protects and maintains LI-COR’s intellectual property portfolio of current and emerging innovations as well as executes intellectual property reviews and strategies. She also negotiates a wide variety of agreements with academic and industrial entities.
Dr. Hillman is a Regional Director of Medical Science Liaisons at Eye Care of Allergan, and currently has eight MSLs that report to him in the western region of the United States. He graduated from Creighton University with a PhD in Pharmacology in 2012. After two years of post-doctoral work at Creighton University Medical Center he transitioned to the pharmaceutical industry as a Medical Science Liaison with Allergan.
Dr. Lenagh
Dr. Lenagh is a Business Development Associate at Streck, Inc. She helps identify and strategically assess internal and external opportunities to create long-term value for Streck, Inc. Prior to joining Streck in 2017, she spent five years working at UNeMed Corporation where she was responsible for evaluating intellectual property landscape and commercial prospects of scientific innovations and promoting their commercialization.
Dr. Madsen is the co-founder, President and CEO of ProTransit Nanotherapy, an Omaha startup built on an UNMC invention. The invention is a nanoparticle delivery platform is comprised of biodegradable, controlled release particles that can be targeted for specific cell binding sites. Dr. Madsen has more than 30 years of experience in developing and launching many different biotechnology products in a wide variety of markets at companies of various sizes. He spent 17 years at Abbott Laboratories in product support, new product development and business development.
Dr. Madsen
The panel discussion is part of Innovation Week, a series of events hosted by UNeMed Corporation as a celebration of the innovation and discovery that happens every year at UNMC.
Earlier this week, UNeMed hosted a Kick-Off event; a panel discussion about the CRISPR gene-editing tool; an instructional workshop on perform patent searches for biomedical research projects; and the 11th annual Research Innovation Awards Banquet.
Learn more about all Innovation Week events at https://www.unemed.com/innovation-week
